

# MDHHS – MCIR Release Notes

Version 2023 – MCIR OLTP 2023 9.6.0 – RFC 220818

Release Date: June 28, 2023

## Forecasting & Assessment Updates (3 items)

1. Meningococcal ACWY (MCV4 or MPSV4) CVX 108 should count as dose 1 for 11–13-year-olds. (Ref. [#2312](#))

Age: 11 years 1 month: Provider site after age 11 years.

Meningoc ACWY (MCV4 or MPSV4)	1	11 Years 1 Month	08/15/2018	Central MI DHD - Isabella County	Unknown
-------------------------------	---	------------------	------------	----------------------------------	---------

<b>Meningococcal</b>	2	07/03/2023	07/03/2023
----------------------	---	------------	------------

Correct

School test site

<b>Meningococcal</b>	Complete
----------------------	----------

Age: 11 years

Meningococcal Conjugate	08/15/18 Meningoc. ACWY (MCV4 or MPSV4)							Up-To-Date	07/03/2023	07/03/2023
-------------------------	---	--	--	--	--	--	--	------------	------------	------------

<b>Vaccine*</b>	Meningoc ACWY (MCV4 or MPSV4) CVX 108
-----------------	---------------------------------------

<b>Meningococcal</b>	2	07/03/2023	07/03/2023	07/03/2024
----------------------	---	------------	------------	------------

<b>Meningococcal</b>	Complete
----------------------	----------

Shows complete for school for meng.

Correct CVX code 108 counted at age 11 for 1<sup>st</sup> dose [MCV4](#)

Age: 13 years 10 months: Test of over 13 years receiving MCV4 over 13 years of age, forecasting dose 2 at age 16 years.

<b>Meningococcal Conjugate</b>	MCV4 (Menactra or Menveo)	1	13 Years 10 Months	01/01/2023	MDHHS Nurse Educators	Unknown
--------------------------------	---------------------------	---	--------------------	------------	-----------------------	---------

<b>Meningococcal</b>	2	02/03/2025	02/03/2025	02/03/2026
----------------------	---	------------	------------	------------

correct- forecasting for dose at age 16 years

School Test site

Meningococcal Conjugate	01/01/2023
-------------------------	------------

<b>Meningococcal</b>	Complete
----------------------	----------

Correct

For more information:

[IIS: Clinical Decision Support \(CDSi\) | CDC](#)

[Vaccines Required for School Entry in Michigan](#)

[Routine Recommendations for Meningococcal Vaccines](#)

[Birth-18 Years Immunization Schedule – Healthcare Providers | CDC](#)

2. **Forecast to “consider” recommendation for PCV20 five years after completion of PCV13/PPSV23 for those who are 65 years and older.** (Ref. #[2302](#))

Shared clinical decision-making is recommended regarding administration of PCV20 for adults aged ≥65 years who completed their vaccine series with both PCV13 and PPSV23. Requested an update for PCV20 with updated guidance to provide a “consider” recommendation for PCV20 in MCIR.

Age: 70 years 8 months Tested in UAT:

<b>Pneumococcal Adult</b>	06/01/2020 PCV13 (Pneumovax) 67yrs 8mos	07/05/2021 PPSV23 (Pneumovax) 68yrs 9mos			Consider Next Due 07/05/2026
<b>PCV20</b>		Consider	07/05/2026	07/05/2026	07/05/2026

Forecasting is correct for considering PCV20 in 5 years.

Age: 73y 5m Tested in UAT:

<b>Pneumococcal Adult</b>	06/07/2021 PPSV23 (Pneumovax) 71yrs 5mos	06/14/2023 PCV13 (Pneumovax) 73yrs 5mos			Consider Next Due 06/14/2028
<b>PCV20</b>		Consider	06/14/2028	06/14/2028	06/14/2028

This is forecasting correctly for consider in 5 years.

Age: 72 years 5 months Tested in UAT:

<b>Pneumococcal Adult</b>	06/06/2016 PCV13 (Pneumovax) 65yrs 4mos	06/05/2023 PPSV23 (Pneumovax) 72yrs 4mos			Consider Next Due 06/05/2028
<b>PCV20</b>		Consider	06/05/2028	06/05/2028	06/05/2028

This is forecasting correctly for consider in 5 years.

For more information:

[https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf?utm\\_campaign=&utm\\_medium=email&utm\\_source=govdelivery](https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf?utm_campaign=&utm_medium=email&utm_source=govdelivery)

[https://www.immunize.org/askexperts/experts\\_pneumococcal\\_vaccines.asp#rec\\_adult](https://www.immunize.org/askexperts/experts_pneumococcal_vaccines.asp#rec_adult)

[PneumoRecs VaxAdvisor \(cdc.gov\)](#)

[Shared Clinical Decision-Making: PCV20 Vaccination for Adults 65 Years or Older-February 2, 2023 \(cdc.gov\)](#)

[Adult Immunization Schedule – Healthcare Providers | CDC](#)

3. All histories of 2 doses of HepB-CpG (HepB-CpG) separated by 4 weeks should be called Series Complete. Histories with 1 HepB adult dose and 1 HepB-CpG (HepB-CpG) dose should forecast another dose and should forecast the 3-dose schedule. (Ref. #1747)

Examples of 3-dose schedule cases:

**Case 1:**

Hepatitis B						
Hep B (adult)	1	62 Years 9 Months	01/01/2023	MDHHS Nurse Educators	Unknown	<a href="#">Delete</a>
Hep B adjuvanted (Heplisav-B)	2	62 Years 11 Months	03/01/2023	MDHHS Nurse Educators	Unknown	<a href="#">Delete</a>

Hepatitis B	YES	3	04/26/2023	04/26/2023	04/26/2023
-------------	-----	---	------------	------------	------------

Forecasting for "Hepatitis B" dose 3 at 16 weeks after dose 1 and 8 weeks after dose 2 for Hep B for accelerated, recommended and overdue.

**Case 2:**

Hepatitis B	11/20/1985 Hep B (ped/adol) 1mo 2dys	12/20/1985 Hep B (ped/adol) 2mos 2dys	02/27/2023 Hep B adjuvanted (Heplisav-B) 37yrs 4mos	Series Complete
-------------	---	--	---	-----------------

Accepts HepB (Heplisav-B) as dose 3 of HepB series.

**Case 3:**

Hepatitis B	01/24/2023 Hep B (adult) 68yrs 6mos	02/28/2023 Hep B adjuvanted (Heplisav-B) 68yrs 7mos	05/01/2023 Hep B adjuvanted (Heplisav-B) 68yrs 9mos	Series Complete
-------------	---	---	---	-----------------

Accepts two doses of HepB (Heplisav-B) as Series Complete with two doses at least 4 weeks apart.

**Case 4:**

Hepatitis B	06/01/2023 Hep B adjuvanted (Heplisav-B) 42yrs 9mos	Up-To-Date Next Due 06/29/2023		
Heplisav-B	2	06/29/2023	06/29/2023	07/27/2023

History of one dose of HepB (Heplisav-B) will forecast Heplisav-B as dose 2 in accelerated and recommended at 4 weeks after dose 1. Overdue is 8 weeks after dose 1.

## General

The FERPA “No Consent” box on Non-Medical Waivers has been removed on Waiver Reports for schools due to the new waiver process. (Ref. #[2363](#))

If you have questions or need assistance, please contact your Field Representative, MCIR Region, or MCIR SOM Help Desk at [MDHHS-MCIRHelp@michigan.gov](mailto:MDHHS-MCIRHelp@michigan.gov).